Neuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
November 12 2020 - 4:05PM
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical
technology company focused on designing, developing and marketing
products that improve the quality of life for patients who suffer
from psychiatric disorders, today announced that the management
team will present at the Canaccord Genuity Virtual MedTech &
Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET. A
live audio webcast of the conference presentation will be available
online at the investor relations page of the Company’s website at
ir.neuronetics.com. A replay of the webcast will
be archived on the website for approximately 90
days.
About NeuroneticsNeuronetics, Inc. is a
commercial-stage medical technology company focused on designing,
developing, and marketing products that improve the quality of life
for patients who suffer from psychiatric disorders. Our first
commercial product, the NeuroStar® Advanced Therapy System, is a
non-invasive and non-systemic office-based treatment that uses
transcranial magnetic stimulation, or TMS, to create a pulsed,
MRI-strength magnetic field that induces electrical currents
designed to stimulate specific areas of the brain associated with
mood. The system is cleared by the United States Food and Drug
Administration, or FDA, for the treatment of major depressive
disorder in adult patients who have failed to achieve satisfactory
improvement from prior antidepressant medication in the current
episode. NeuroStar is also available in other parts of the world,
including Japan, where it is listed under Japan’s national health
insurance. Additional information can be found at
www.neuronetics.com.Investor Contact:Mark R.
KlausnerWestwicke
Partners443-213-0501
ir@neuronetics.comMedia
Contact:Chelsey MankoVault
Communications610-455-2778
cmanko@vaultcommunications.com
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuronetics (NASDAQ:STIM)
Historical Stock Chart
From Sep 2023 to Sep 2024